Tests venetoclax and azacitidine with HAAG in newly diagnosed acute myeloid leukemia
Tests venetoclax, azacitidine and HAAG together in adults with newly diagnosed leukemia.
Plain-language title generated from the registry record
Registry title: Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients
Key facts
- Where
- Suzhou, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-65 with newly diagnosed intermediate or high-risk acute myeloid leukemia (AML), not the promyelocytic type, who have had no earlier chemotherapy or targeted therapy.
- Age
- 18 to 65 years
- Sex
- All sexes
- Disease stage
- Newly diagnosed intermediate or high-risk AML (WHO 2022 classification), not acute promyelocytic leukemia (APL)
- Earlier treatment
- No earlier chemotherapy or targeted therapy
Main reasons for not taking part
- AML that developed from chronic myelogenous leukemia
- Acute promyelocytic leukemia (type M3)
- A second cancer that needs treatment
- Uncontrolled active infection
- HIV infection, or active hepatitis B or hepatitis C
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06394011, who can take part
Where in China
- The First Affiliated Hospital of Soochow UniversitySuzhou, ChinaContact: Xiaowen Tang, Ph.DTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The First Affiliated Hospital of Soochow University
- Trial code
- NCT06394011
- Record updated
- 1 May 2024
- Original description
The purpose of this study is to evaluate the efficacy and safety of VA combined with HAAG in the induction treatment of newly diagnosed acute myeloid leukemia.Read full original descriptionShow less
A Single-center, Single-arm, Prospective Clinical Study on the Efficacy and Safety of Venetoclax and Azacitidine Combined With HAAG in the Induction Treatment of Intermediate and High-risk Acute Myeloid Leukemia
The purpose of this study is to evaluate the efficacy and safety of VA combined with HAAG in the induction treatment of newly diagnosed acute myeloid leukemia.
Inclusion: Newly diagnosed intermediate and high-risk AML according to the WHO (2022) classification of acute myeloid leukemia (non-APL); Age 18-65; ECOG score: 0-2; No history of previous chemotherapy or target therapy; Serum total bilirubin <= 2 times the upper limit of normal (ULN), alanine aminotransferase (ALT) <= 1.5 times ULN, aspartate aminotransferase (AST) <=1.5 times ULN; Creatinine clearance rate >=30 mL/min; Serum lipase <= 1.5 times ULN, amylase <= 1.5 times ULN; Capable to understand and willing to participate in this study, signed the informed consent form.
Exclusion: Patients with a second malignancy requiring treatment; Patients with uncontrolled active infection; Patients with HIV infection; Patients with active hepatitis B or hepatitis C infection; Patients with left ventricular ejection fraction < 0.5 by echocardiography or grade III/IV cardiovascular dysfunction according to the New York Heart Association Classification; Patients with hepatic and renal inadequacy: total serum bilirubin >=2.0 mg/dl, AST >=3 times ULN, serum creatinine clearance (Ccr) <50 ml / min; AML transformed with chronic myelogenous leukemia; Acute promyelocytic leukemia (type M3); Patients with arterial oxygen saturation (SpO 2) was <95%; Patients with other commodities that the investigators considered not suitable for the enrollment.